News and Publications
Press Releases
Gatehouse Bio Announces Upcoming Presentation at RNA Leaders Europe Congress
BOSTON–(BUSINESS WIRE)–Gatehouse Bio, a TechBio company utilizing AI to decode the landscape of small RNAs (sRNAs) and digitally design precision oligonucleotide therapeutics, announced today that
Gatehouse Bio Extends Its Partnership with AstraZeneca to Develop RNA Therapeutics for Heart Failure
BOSTON–(BUSINESS WIRE)–Gatehouse Bio, a pioneer in small RNA therapeutics, and AstraZeneca, a global, science-led biopharmaceutical company, are advancing their partnership, to create RNA therapeutics for the
Gatehouse Bio collaborates with AstraZeneca to accelerate new drug discovery
Collaboration will use Gatehouse Bio’s AI-Powered Analytics Platform to identify potential drug targets in respiratory and cardiovascular diseases
Gatehouse Bio Receives FDA Support for AI-Powered Pathway Analytics Platform
Platform uncovers biomarkers that track progression of Huntington’s disease 20 years before symptomatic onset
Gatehouse Bio to Accelerate its Biomarker Discovery Platform and Services at IndieBio
… early-stage biotech startup based in Boston who has developed a software platform technology to identify small RNA biomarkers, announced today it will participate in
Publications
Small RNA predictors for Alzheimer’s Disease
David W Salzman, Alan P Salzman, Neal C Foster, Nathan S. Ray
Methods for identifying and using small RNA predictors
D Salzman US Patent App. 17/313,191 US Patent 11,028,440 US Patent 10,889,862
The KRAS-variant and its impact on normal breast epithelial cell biology
Song-yi Jung, Poonam Malhotra, Kiana C Nguyen, David Salzman, Yue Qi, Ethan
A germline microRNA-based biomarker signature of immune-associated toxicity to anti-PD1/PDL1 therapy.
Joanne B Weidhaas, Aaron Wolfe Scheffler, David Salzman, Anusha Kalbasi, Kirk Wilenius,
Identification of Biomarkers for Early-Detection and Monitoring of Huntington Disease
DW Salzman, J Bregu, NS Ray, RH Myers NEUROTHERAPEUTICS 15 (4), 1213-1214
